Screener
Pacific Biosciences of California PACB Business Segments — Merger-related expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.
The source filing: Pacific Biosciences of California’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:03 PM EST
- Fiscal year
- FY2025
- Accession
- 0001299130-26-000034
| (In thousands) | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Sales and marketing | 72,972 | 87,244 | 79,287 |
| General and administrative | 68,521 | 87,773 | 90,531 |
| Impairment charges | 15,000 | 184,500 | — |
| Merger-related expenses | — | — | 9,042 |
| Change in fair value of contingent consideration | (18,700) | (850) | 15,060 |
| Amortization of acquired intangible assets | 364,541 | 18,006 | 6,157 |
| Loss on extinguishment of debt | — | — | 2,033 |
| Gain on debt restructuring | — | (154,407) | — |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Pacific Biosciences of California's business segments — merger-related expenses?
- Pacific Biosciences of California (PACB) reported business segments — merger-related expenses of $0 in Q4 2025.
- What does business segments — merger-related expenses mean?
- These are non-recurring costs incurred by the reportable segment specifically associated with the acquisition or integration of other business entities. Such expenses may include legal fees, consulting costs, and integration-related personnel expenses. Identifying these costs allows investors to isolate the impact of inorganic growth strategies from the segment's core operational performance.
Ask your AI about Pacific Biosciences of California's business segments — merger-related expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude